John Buse - Articles and news items

Novo Nordisk Logo

IDegLira demonstrates superior glycaemic control and weight loss with a low rate of hypoglycaemia for patients uncontrolled on basal insulin

Industry news / 3 December 2013 / Novo Nordisk

New phase 3 data from the investigational therapy IDegLira were presented at the World Diabetes Congress of the International Diabetes Federation…

New epidemiological data provide additional safety evidence for Lantus®

Industry news, News / 11 June 2012 / Sanofi

New results of a large-scale epidemiological program announced…

BYETTA® approved for use with insulin glargine in the U.S.

Industry news, News / 19 October 2011 / Eli Lilly and Company

FDA has approved a new use for BYETTA® (exenatide) injection….


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...